With a market capitalization (market cap) of $1.08B — a measure of how much the company is worth — City Therapeutics Inc. ranks #2,339 among the 2,394 companies tracked, and 337th in Healthcare as of November 20, 2026. Shares trade at $20.15, up 9.86% on the day.
As of November 20, 2026 · Prices may be delayed
of 2,394 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series and can differ when the share count changes. Returns below show the total change over each period. Use the CAGR calculator to calculate an annualized return. CAGR calculator. Market cap vs. stock price.
Listed less than one year ago
Listed less than one year ago
Listed less than six months ago
Listed this year; no prior year-end value to compare
Listed less than five years ago
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation November 20, 2026. The headline market cap is from the ranking update on November 20, 2026.
| Year | As of | Market cap | Annual change | Share-price close |
|---|---|---|---|---|
| 2026Latest available | Nov 20, 2026 | $1.07B | — | $20.22 |
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Ranking figure $1.08B as of November 20, 2026.
Market cap = share price × shares outstanding.
City Therapeutics Inc.'s ranking market cap is the reported market cap from the latest ranking update, with a share price of $19.32 as of November 20, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1.07B on November 20, 2026. See how the ranking works.
Current shares outstanding are unavailable from the latest quote. Shares outstanding vs. float.
Book equity: assets minus liabilities on the latest annual report.
Book equity (net worth) data unavailable for FY 2019
FY 2019
FY 2019
FY 2019
FY 2019
FY 2019
FY 2019
FY 2019
FY 2019
FY 2019
FY 2019
FY 2019
FY 2019
FY 2019
FY 2019
Quote as of . Prices may be delayed. Day figures refer to the quote's trading session.
Latest quote: $19.32. The headline price of $20.15 is from the ranking update on Nov 20, 2026. These updates can differ in timing.
Largest U.S.-listed companies in the same sector. These companies may serve different markets.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #11 | Eli Lilly and Company LLY | $1.27T | +0.08% |
| #21 | Johnson & Johnson JNJ | $651.56B | +1.26% |
| #23 |
City Therapeutics, Inc. is a biotechnology company specializing in next-generation RNA interference (RNAi) therapeutics. The company is based in Cambridge, MA. The company engineers potent, specific, and durable RNAi trigger molecules combined with precision targeting ligands to deliver siRNAs beyond the liver to tissues such as ocular and central nervous system targets.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2019.
Visit websiteAs of November 20, 2026, City Therapeutics Inc. (CTY) is worth $1.08B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. Book equity is blank on this page when annual book value per share is missing. Market cap is the market value of the outstanding shares. As of November 20, 2026, its market cap is $1.08B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
City Therapeutics Inc. ranks #2,339 among the 2,394 companies tracked on MarketCapLens. In Healthcare it ranks #337 of 350.
Financial figures are annual and labeled with their fiscal year (FY). Current-price P/E uses the latest available share price and annual earnings per share.
FY 2019
Return on equity data unavailable for FY 2019
FY 2019
Return on assets data unavailable for FY 2019
FY 2019
| $509.89B |
| +1.69% |
| #32 | Merck & Co., Inc. MRK | $331.85B | +1.31% |
| #36 | UnitedHealth Group Incorporated UNH | $308.44B | +4.08% |
| #39 | Novartis AG NVS | $286.75B | +0.36% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2336 | SI-BONE, Inc. SIBN | $1.08B | +0.85% |
| #2337 | RPC, Inc. RES | $1.08B | -3.85% |
| #2338 | Kardigan, Inc. KARD | $1.08B | -3.99% |
| #2340 | Adient plc ADNT | $1.07B | -4.97% |
| #2341 | Alpha Tau Medical Ltd DRTS | $1.07B | +2.30% |
| #2342 | Liberty Capital Corporation GLIBA | $1.07B | +0.39% |
City Therapeutics Inc.’s ranking market cap of $1.08B comes from the same snapshot as the rest of this site, as of November 20, 2026. It is not share price multiplied by the FY 2019 weighted-average share count of 0. The historical market-cap series last observed $1.07B on November 20, 2026.
City Therapeutics Inc. (CTY) shares trade at $20.15, up 9.86% on the day, as of November 20, 2026.
Live P/E is share price divided by annual earnings per share. It is blank when earnings are missing, zero, or negative — not a 0× multiple.